Fibulin-1C, C1 Esterase Inhibitor and Glucose Regulated Protein 75 Interact with the CREC Proteins, Calumenin and Reticulocalbin

Gry Aune Westergaard Hansen¹, Maja Ludvigsen¹, Christian Jacobsen¹, Claudia Cangemi², Lars Melholt Rasmussen², Henrik Vorum³, Bent Honoré¹*

¹ Department of Biomedicine, Ole Worms Allé 3, Building 1182, Aarhus University, DK-8000 Aarhus C, Denmark, ² Department of Clinical Biochemistry and Pharmacology, Center for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark, ³ Department of Ophthalmology, Aalborg University Hospital, Hobrovej 18–22, 9100 Aalborg, Denmark

* bh@biomed.au.dk

Abstract

Affinity purification, immunoprecipitation, gel electrophoresis and mass spectrometry were used to identify fibulin-1C, C1 esterase inhibitor and glucose regulated protein 75, grp75, as binding partners of the CREC proteins, calumenin and reticulocalbin. Surface plasmon resonance was used to verify the interaction of all three proteins with each of the CREC proteins. Fibulin-1C interacts with calumenin and reticulocalbin with an estimated dissociation constant around 50-60 nM. The interaction, at least for reticulocalbin, was not dependent upon the presence of Ca²⁺. C1 esterase inhibitor interacted with both proteins with an estimated dissociation constant at 1 μM for reticulocalbin and 150 nM for calumenin. The interaction, at least for calumenin, was dependent upon the presence of Ca²⁺ with strong interaction at 3.5 mM while no detectable interaction could be found at 0.1 mM. Grp75 binds with an affinity of approximately 3-7 nM with reticulocalbin as well as with calumenin. These interactions suggest functional participation of the CREC proteins in chaperone activity, cell proliferation and transformation, cellular aging, haemostasis and thrombosis as well as modulation of the complement system in fighting bacterial infection.

Introduction

The CREC family consists of a set of multiple EF-hand Ca²⁺-binding proteins [1,2]. The family includes at present reticulocalbin [3], ERC-55 and its splice variants [4,5], reticulocalbin-3 [6], Cab45 and its splice variants [2,7,8] as well as calumenin that is now known to exist as 15 splice variants [2,9–13]. The main localization is in the secretory pathway with few exceptions, where Cab45-C and ERC-55-C are present in the cytosol [2,8] and calumenin-15 shuttles between the cytosol and the nucleus [13]. Few members are found to be secreted out of the cell, calumenin [14,15], a Cab45 variant, Cab45-S [2,16,17] and reticulocalbin which may be found on the cell surface [18].
The functional properties are steadily emerging with links to malignant cell transformation [10,19–22] and stress responses [23,24]. A number of molecular functions have been described especially in connection with calumenin in the endoplasmic reticulum (ER) or sarcoplasmic reticulum (SR) [2,25]. Thus, calumenin interacts with the ryanodine receptor-1 possibly regulating its activity [26]. Also, the interaction with and the inhibition of the vitamin K-dependent γ-carboxylation system has been discovered [27] and a polymorphism in the calumenin gene is reported to influence the dose requirements for warfarin anticoagulation [28]. Recently, calumenin was found to interact with the G551D cystic fibrosis transmembrane conductance regulator (CFTR) protein that is causing cystic fibrosis [29]. Calumenin-15 facilitates filopodia formation by increasing GDF-15 transcription [13]. Besides these intracellular functions a few extracellular functions have been reported by the observation that thrombin activated thrombocytes release calumenin which also may be found in atherosclerotic lesions [30]. In vitro experiments have shown that calumenin may modulate the protein expression of fibroblasts [31]. Most recently, calumenin was found to suppress ERK1/2 signalling and cell migration by protecting fibulin-1 from MMP-13-mediated proteolysis [32].

In order to further reveal functional properties of the CREC proteins we searched for novel protein ligands that may interact with two of the family members, calumenin and reticulocalbin. By column immobilization we purified two proteins against each CREC member, fibulin-1C and C1 esterase inhibitor. By immunoprecipitation of cellular proteins and surface plasmon resonance (SRP) analysis the glucose regulated protein 75, grp75, was identified as interacting partner with calumenin and reticulocalbin. The functional implications of these interactions are further discussed.

Materials and Methods

Plasmid constructs

We have previously described the expression plasmids consisting of pT7-PL with calumenin [10] and pGEX-4T3 with calumenin [33]. The pGEX expression plasmid containing reticulocalbin was a kind gift of Dr. Ozawa [3] and is also described in [33]. The nucleotides of fibulin-1C (IMAGE clone no. 1174460) encoding amino acids 33–683 of fibulin-1C were cloned into the pGEX-4T3 vector. The subcloned cDNA was PCR amplified using the forward primer: 5’-CCC-GAA-TTC-CGA-TGT-CCT-CCT-GGA-GGC-CTG-CT-3’ and the reverse primer: 5’-CCG-CTC-GAG-TCA-GAG-CTC-TGC-AGA-CAC-CAC-AAA-GAT-G-3’. Thus, the N-terminal amino acids 1–32 that includes the signal sequence are not contained in the expressed protein. The plasmids were transformed into competent E. coli cells (DH5α, XL1-Blue or BL21-Codon plus). For expression in MRC-5 V2 cells fibulin-1C (IMAGE clone no. 1174460) was PCR amplified using the forward primer: 5’-CCC-TCT-A-GA-CCC-GCC-GCC-CAT-GGA-G-3’ and the reverse primer: 5’-CCG-CTC-GAG-TCA-GAG-CTC-TGC-AGA-CA-3’. The cDNA was subcloned into pcDNA3.1/zeo(-). PWO DNA polymerase was used for PCR amplification. The plasmids were checked for errors by DNA sequencing using the service facility at MWG Biotech AG (Ebersberg, Germany).

Protein expression and purification

Expression and purification of calumenin encoded by the pT7-PL vector was performed as previously described [10]. In short, E. coli cells were re-suspended in lysis buffer (8 M urea, 100 mM NaH₂PO₄, 10 mM Tris-HCl, pH 8) and added to a Ni²⁺-NTA-agarose column. The Hexa His-calumenin proteins were eluted in elution buffer (lysis buffer at pH 4.5). The pH was adjusted to 8.0 and dithiotreitol was added to a concentration of 100 mM. GST fusions proteins were expressed in E. coli after induction with IPTG. The cells were harvested and re-suspended
in 1x PBS buffer (2.7 mM KCl, 1.8 mM KH$_2$PO$_4$, 10.1 mM Na$_2$HPO$_4$, 140 mM NaCl, pH 7.3). 

Protease inhibitor cocktail, Complete EDTA free from Roche diagnostic, was added and the cells were lysed by sonication and 20% Triton-x-100 treatment. The supernatant was mixed with glutathione-sepharose beads (Pharmacia). The GST fusion protein were eluted from the beads with glutathione elution buffer (10 mM glutathione, 50 mM Tris-HCl, pH 8.0). The GST-reticulocalbin fusion protein was cut with thrombin beads from Sigma overnight. The proteins were dialyzed against 1 x PBS (dialysis tubing 8/32 from KemEnTec, diameter 6 mm, cut off 12–14 kDa) in order to remove glutathione. After dialysis glutathione-sepharose beads were added to remove GST from the solution. The supernatant finally contains the recombinant protein.

Eluted proteins from several protein expressions and purifications were pooled, concentrated and furthermore purified by gel filtration on a Superdex 200 column. The protein concentration was measured with a Non-Interfering Protein Assay Kit from Calbiochem or measured spectrophotometrically at 280 nm. Commercially available C1 esterase inhibitor was obtained from Calbiochem. Recombinant GST-grp75 (AAH00478.1) was obtained from Abnova (Taipei, Taiwan).

**Antibodies**

The purified recombinant reticulocalbin and calumenin were used for immunization of rabbits and for affinity purification of anti-calumenin and anti-reticulocalbin polyclonal antibodies essentially as previously described [14]. Rabbit polyclonal antibody H-190 was obtained from Santa Cruz Biotechnology, which recognizes an epitope common to all fibulin-1 isoforms (A–D). Monoclonal anti-fibulin-1 antibody was kindly provided by Dr. W. Scott Argraves, Medical University of South Carolina. Monoclonal anti-grp75 antibody was obtained from Biosite.

**Immunoprecipitation**

MRC-5 V2 cells were grown in Dulbeccos modified Eagles media (DMEM) with GlutaMAX I containing 10% (v/v) FBS and antibiotic (100 units/ml penicillin and 100 μg/ml streptomycin). Labelling of cells in vivo with L-[35S]–Met and L-[35S]–Cys were done in labelling medium with 2.5 ml DMEM, 41.5 ml DMEM without methionin, cystein and glutamine, 0.5 ml GlutaMAX I, 5ml dialyzed FBS and 0.5 ml penicilin/streptomycin. Incubation over night in 30 mm tissue cluture test plates from TPP (Trasadingen, Switzerland) with 3 ml labelling medium containing 0.1 mCi/ml of Pro-mix (SJQ 0079) from GE Healthcare. The cells were dissolved in lysis buffer (150 mM NaCl, 5 mM CaCl$_2$, 50 mM Tris-HCl, pH 7.4, 0.5% Triton x-100, 0.5% Na-deoxycholate). Antiserum, 6.25 mg/ml BSA, 1 x NCTTAM buffer (150 mM NaCl, 5 mM CaCl$_2$, 50 mM Tris-HCl, pH 7.4, 1% Triton x-100, 1 mg/ml BSA, 20 mM methionin, 0.02% NaN$_3$) were added to the cell lysate and incubated for one hour at room temperature. Immunocomplexes were pelleted by incubation with GammaBind G Sepharose beads from GE Healthcare for 30 minutes and centrifuged. The pellets were washed twice with 1 x NCTTAM buffer and twice with ice-cold 2 times distilled H$_2$O and the immunocomplexes were eluted with 2 x Laemmli buffer (0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 0.005% bromophenol blue) for 10 minutes at 95°C followed by centrifugation. The immunocomplexes were precipitated with ethanol and used for 2D-PAGE analyses.

**Affinity purification of reticulocalbin and calumenin interacting proteins from human placenta**

Recombinant reticulocalbin and calumenin from the protein expressions were dialyzed in coupling buffer (0.1 M NaHCO$_3$, 0.5 M NaCl, pH 8.3) and then concentrated in centriplus 3 and centricon YM-3 tubes from Amicon. CNBr activated sepharose 4B was swelled and washed
with 200 ml 1 mM HCl and then mixed with coupling buffer (reference column) and concentrated reticulocalbin and calumenin, respectively. After the coupling excess ligand was washed away from the gel with coupling buffer and blocking buffer (0.1 M Tris-HCl, pH 8.0) was added to block any remaining active groups. Afterwards the gel matrix was washed in buffers with three cycles of alternating pH to completely remove excess of uncoupled ligand. Each cycle consisted of a wash with washing buffer 1 (0.1 M Na-acetate, 0.5 M NaCl, pH 4.0) followed by a wash with washing buffer 2 (0.1 M Tris, 0.5 M NaCl, pH 8.0). The columns were packed with the gel matrix equilibrated in MB-buffer (2 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 140 mM NaCl, pH 7.4). Equal volumes of dialyzed placenta extract prepared as previously described [33] were added to the columns with immobilized recombinant reticulocalbin and calumenin and the reference columns without reticulocalbin and calumenin, respectively. The columns were then washed in MB-buffer before elution with MB-buffer containing 200 mM, 400 mM, 600 mM, 800 mM, 1000 mM NaCl and finally 1000 mM NaCl with EDTA (10 or 20 mM), 10 mM HEPES, pH 7.4. The eluates were up-concentrated and analyzed for potential protein ligands by gel electrophoresis and subsequently identified by mass spectrometry.

**Gel electrophoresis**

One-dimensional (1D) and two-dimensional (2D) polyacrylamide gel electrophoresis (PAGE) as well as silver staining were essentially performed as previously described [34].

**Cell culture and transfection assay**

MRC-5 V2 cells were grown as monolayer cultures in DMEM supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 50 γg/ml streptomycin). To establish transfected cell lines overexpressing fibulin-1C, plasmid encoding fibulin-1C in pcDNA3.1/zeo (-) was transfected into human MRC-5 V2 fibroblast cells using FuGENE 6 transfection reagent (Roche Diagnostics).

**Mass spectrometry**

Gels containing protein spots were re-swelled in water and the protein spots of interest were cut out and treated as previously given [33].

**Immunofluorescence microscopy**

MRC-5 V2 cells were grown on coverslips to 60–70% confluence. Then the cells were fixed for 10 min with 3.7% formalin and subsequently washed with 1 x PBS. The cells were permeabilized with 0.1% Triton X-100 and 3.7% formalin and washed again. The formalin fixed MRC-5 V2 cells were double stained with rabbit anti-reticulocalbin antibody, rabbit anti-calumenin antibody, mouse anti-grp75 or mouse anti-fibulin-1 mAb 3A11 for one hour at 37°C in a moist chamber. The cells were washed repeatedly in 1 x PBS and incubated with donkey anti rabbit IgG (Alexa Flour 594 conjugated) or donkey anti mouse IgG (alexa flour 488 conjugated) secondary antibody diluted 1:5000 for one hour at room temperature. For nucleus staining a DAPI solution diluted 1:50000 was added and incubated for 10 min. Upon washing the cells were mounted with Fluorescence mounting medium from DAKO.

**Immunohistochemistry**

Normal appearing, non-atherosclerotic internal mammary artery biopsies, collected at coronary bypass surgery as described before [35], and inner lining of atherosclerotic carotid artery, collected at endarterectomy surgeries, were employed for immunohistological analyses. Upon
collection, the specimens were fixed in PBS (10 mmol/L phosphate, 150 mmol/L NaCl, pH 7.2), buffered 4% formaldehyde and subsequently embedded in paraffin. Sections of arterial samples (4 μm) were incubated overnight at 4°C with rabbit polyclonal antibody H-190 (Santa Cruz Biotechnology, Inc.; dil.:1/100), which recognizes an epitope common to all fibulin-1 isoforms (A-D). Envision system HRP-conjugated secondary antibodies were used (K4002, Dako) for detection. Diaminobenzidine (DAB+, K3468; Dako) was applied for 50 seconds and stopped in H2O. Control sections were incubated with secondary antibody only. Calumenin and reticulocalbin staining was done with rabbit polyclonal antibodies affinity purified and tested as previously described [14] using UltraView Universal Alkaline Phosphatase Red Detection Kit from Ventana Medical Systems.

Surface plasmon resonance (SPR)

Interaction analyses were performed using Biacore 2000/3000 instrument using CM5 sensor chips (GE Healthcare). Amine-coupling reagents (N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide were used for activation of the sensor chip, creating a reactive ester on the surface. After reticulocalbin and calumenin immobilization, the sensor surface was deactivated with 1 M ethanolamine, pH 8.5, to block the remaining unreacted groups. Fibulin-1C and C1 esterase inhibitor were dissolved with running buffer (10 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 1mM EGTA and 0.005% Tween 20, pH 7.4), and binding experiments were performed at 25°C in running buffer. A control flow cell with an activated but uncoupled chip was used as a reference to subtract nonspecific binding. Regeneration of the sensor chip after each analysis cycle was performed with 10 mM glycine, 20 mM EDTA, 500 mM NaCl and 0.005% Tween 20, pH 4.0. Due to high affinity interaction this buffer was not sufficient to remove grp75 from the chips. Instead a buffer containing 0.05% SDS was needed to remove grp75. Sensorgrams show SPR signal against time and is expressed in relative response units as the difference in response between the flow cell with immobilized calumenin or reticulocalbin and a control flow cell. Data were analyzed by global fitting to a 1:1 Langmuir binding model of both the association and dissociation phases for one or several concentrations, using BIAevaluation 4.1 software (GE Healthcare). Apparent equilibrium dissociation constant (KD) was calculated from the ratio of the dissociation and association rate constants (k_off/k_on).

Tissue

The local ethical committee of the County of Aarhus and the regional committee for Biomedical Research Ethics of Southern Denmark (approval number S-20140202) approved the use of human tissue. All patients signed informed consent.

Results

Affinity purification of calumenin and reticulocalbin interacting proteins from placenta

Several liters of placenta extract were equally applied to a column with immobilized calumenin and a parallel column without coupled calumenin. After washing in several column volumes of MB-buffer with 140 mM NaCl the proteins from each of the columns were eluted with a step-wise gradient using increasing concentrations of NaCl from 0.2 M to 1 M and finally 1 M NaCl with the inclusion of EDTA. Eluates were concentrated and analyzed by 1D-PAGE (Fig 1A) or 2D-PAGE (Fig 1B). Apparently, the columns bind a number of proteins non-specifically. However, one band around 80–100 kDa was seen faintly in the 0.4 M fraction and with increasing intensity using steadily higher salt concentrations and it also appeared in the elution containing
EDTA. The band marked (EDTA 100) was excised from the gel and subjected to *in gel* tryptic digestion. MALDI-TOF analysis revealed that the band contained fibulin-1 (Table 1). The band also contained traces of thrombospondin-1, which we previously have identified as a calumenin interacting protein [33]. We further analyzed the fractions by 2D-PAGE as seen in Fig 1B. Although a number of unspecific proteins also are apparent with this analysis clearly a similar elution pattern could be seen. A set of co-migrating protein spots were found around 80 kDa in the elution from the calumenin column which was clearly absent from the reference column (gray arrows, Fig 1B). In addition to the 80-kDa co-migrating proteins a string of spots around 20 kDa was eluted from the calumenin column using increasing concentrations of NaCl and also appeared in the elution containing EDTA (gray arrowheads, Fig 1B). As indicated in Fig 1B representatives of these proteins were excised from the gels for identification by mass spectrometry (1948–5 and 1950–1). The representatives revealed that the 80-kDa protein was fibulin-1 and the 20 kDa protein apparently an N-terminal fragment of fibulin-1 (Table 1). From the 2D-PAGE analysis it was further apparent that one diffuse spot revealed a quite different elution profile. The spot is located around 80 kDa in an acidic position (pI ≈ 3 to 4). The spot was found in the elutions containing 0.2 and 0.4 M NaCl and was not apparent at elutions containing higher salt concentration. This spot was excised from the gels containing the elution with 0.2 M NaCl (Spot No. 2006–1). The MALDI TOF analysis revealed that the protein was C1 esterase inhibitor (Table 1).

A similar analysis was performed of placenta proteins eluted from a reticulocalbin column in parallel with a reference column. Only the 0.2 M NaCl and 0.4 M NaCl elutions are shown (Fig 2). Again several proteins bind unspecifically to the columns. However, although the intensities of the spots are low, one acidic diffuse spot located around 80 kDa (pI ≈ 3 to 4) is especially seen in the elution fraction with 0.2 M NaCl (spot 2018–2) but also seen to some extend in the fraction with 0.4 M NaCl from the reticulocalbin column. The spot was not detected in the corresponding elution fractions from the reference column. Excision of the spot (No. 2018–2) with subsequent MALDI-TOF analysis identified the protein as C1 esterase inhibitor (Table 1). In the 0.4 M NaCl elution fraction several 80 kDa partly co-migrating spots was seen from the reticulocalbin column that were absent from the reference column (spots No. 2020–2 and 2020–3). They were also seen to some extend in the elution fraction using 0.2 M NaCl from the reticulocalbin column but not from the reference column. Both spots were excised for MALDI-TOF analysis and were identified as fibulin-1 (Table 1).

Thus, the affinity purification of placenta proteins using immobilized calumenin as well as immobilized reticulocalbin identified fibulin-1 as an interacting protein with both CREC proteins. Fibulin 1 exists in four variants A, B, C and D and the identified fibulin indicated that the purified protein was of the C type. In addition C1 esterase inhibitor was found to interact with both CREC proteins. In order to minimize artefact protein identifications we focused on spots that were highly enriched in the analytical eluates showing a “consistent” elution pattern by being present in several fractions. SPR was subsequently used to verify these interactions.

**Surface plasmon resonance verification of fibulin-1C interaction with reticulocalbin and calumenin**

SPR was used to verify the interactions between the identified proteins and immobilized reticulocalbin and calumenin as shown in Fig 3. Various concentrations of recombinant GST-fibulin-1C were applied to the chip with immobilized reticulocalbin in presence of Ca^{2+} (Fig 3A). A large increase in response units is seen with the addition of GST-fibulin-1C in the association phase. The dissociation phase starts around 600 seconds by the addition of buffer. The dissociation constant is estimated to be around 60 nM (k_{diss}/k_{ass}). No detectable binding was seen
Fig 1. Affinity purification of calumenin binding proteins from extract of placenta. Equal volumes of homogenized human placenta were applied to a column with immobilised calumenin and to a column without calumenin. Both columns were eluted with stepwise increasing concentrations of NaCl from 0.2 M to 1 M as indicated and finally with 1M NaCl containing 20 mM EDTA. Equal volumes of concentrated samples were applied to 1D-PAGE (A) and 2D-PAGE (B) gel electrophoresis with subsequent silver staining. The acidic side and the basic side of the first dimensions of the 2D gels are indicated. Several proteins were eluted from the calumenin column as well as the reference column. The band marked EDTA 100 and the spots marked 2006–1, 1948–5 and 1950–1 were excised from the rehydrated gels and subjected to mass spectrometry identification as given in Table 1.

doi:10.1371/journal.pone.0132283.g001
| Protein spot | Measured mass | Computed mass | Peptides identified by MALDI | Position of peptide in protein | Peptide coverage | Protein identification |
|-------------|--------------|---------------|-------------------------------|-------------------------------|-----------------|-----------------------|
| EDTA 100    | 1989.888     | 1989.916      | IIEVEEEQEDPYLNDR             | 164–179                      | 16%             | Fibulin 1, CAQ09097.1 (1–683 amino acids) |
| 1174.566    | 1174.536     | GYHLNENEGTR   |                              | 344–353                      |                 |                       |
| 1177.560    | 1177.540     | TGYYFDGISR    |                              | 386–395                      |                 |                       |
| 2336.247    | 2336.231     | ITYHLSFPTNIIQAPAVVFR |                        | 586–605                      |                 |                       |
| 2856.376    | 2856.304     | MGPSSAVPGDSMQLAITEGNEEGFFTTR |                    | 606–633                      |                 |                       |
| 1997.106    | 1997.141     | KVSHPGAVVALKPVPEPR |                          | 634–652                      |                 |                       |
| 800.477     | 800.500      | DLLTVK        |                              | 653–659                      |                 |                       |
| 1948–5      | 1989.910     | IIEVEEEQEDPYLNDR |                          | 164–179                      | 21%             | Fibulin 1, CAQ09097.1 (1–683 amino acids) |
| 1438.648    | 1438.687     | LGESCINTVGSFR |                              | 229–241                      |                 |                       |
| 815.354     | 815.370      | NVPNGR        |                              | 337–343                      |                 |                       |
| 1174.551    | 1174.536     | GYHLNENEGTR   |                              | 344–353                      |                 |                       |
| 1022.468    | 1022.460     | VCNSPGSFR     |                              | 373–381                      |                 |                       |
| 1177.550    | 1177.540     | TGYYFDGISR    |                              | 386–395                      |                 |                       |
| 1309.516    | 1309.521     | MCVDNECQR     |                              | 396–405                      |                 |                       |
| 1457.589    | 1457.606     | CLAFECPENYR   |                              | 551–561                      |                 |                       |
| 1369.599    | 1369.597     | CERLPCHENR    |                              | 568–577                      |                 |                       |
| 2336.269    | 2336.231     | ITYHLSFPTNIIQAPAVVFR |                      | 586–605                      |                 |                       |
| 2856.411    | 2856.304     | MGPSSAVPGDSMQLAITEGNEEGFFTTR |                 | 606–633                      |                 |                       |
| 2337.240    |              | ITYHLSFPTNIIQAPAVVFR |                       |                               |                 |                       |
| 1950–1      | 1269.561     | 1269.554      | DCSLPYATESK                 | 49–59                         | 5               | Fibulin 1, CAQ09097.1 (1–683 amino acids) |
| 1234.521    | 1234.482     | CCHCCLGR      |                              | 109–117                      |                 |                       |
| 1790.851    | 1790.816     | SQETGLDLDVGLQETDK |                           | 147–163                      |                 |                       |
| 2006–1      | 1263.670     | 1263.670      | TNLESILSYPK                 | 191–201                      | 21%             | C1 inhibitor, BAF85743 (1–500 amino acids) |
| 1217.584    | 1217.586     | DFTCVHQALK    |                              | 202–211                      |                 |                       |
| 1825.916    | 1825.968     | GVTSVQIFHSPDLAIR |                         | 217–233                      |                 |                       |
| 909.458     | 909.455      | TLYSSSPR      |                              | 242–249                      |                 |                       |
| 1115.581    | 1115.582     | LDLPSDTR      |                              | 277–286                      |                 |                       |
| 1191.604    | 1191.585     | TRMEFFHK      |                              | 308–316                      |                 |                       |
| 1430.744    | 1430.755     | YPVAHFDOTLTK  |                              | 330–341                      |                 |                       |
| 1885.859    | 1885.935     | HRLEDMEGALPSVFK |                         | 365–380                      |                 |                       |
| 1184.698    | 1184.691     | FQPTLLTLPR    |                              | 391–400                      |                 |                       |
| 1185.700    |              | FQPTLLTLPR    |                              |                               |                 |                       |
| 2018–2      | 1263.644     | 1263.670      | TNLESILSYPK                 | 191–201                      | 23%             | C1 inhibitor, BAF85743 (1–500 amino acids) |
| 1217.593    | 1217.586     | DFTCVHQALK    |                              | 202–211                      |                 |                       |
| 1825.884    | 1825.968     | GVTSVQIFHSPDLAIR |                         | 217–233                      |                 |                       |
| 909.452     | 909.455      | TLYSSSPR      |                              | 242–249                      |                 |                       |
| 1115.589    | 1115.582     | LDLPSDTR      |                              | 277–286                      |                 |                       |
| 1191.590    | 1191.585     | TRMEFFHK      |                              | 308–316                      |                 |                       |
| 1558.807    | 1558.850     | KYPVAHFDOTLTK  |                                | 329–341                      |                 |                       |
| 1885.866    | 1885.935     | HRLEDMEGALPSVFK |                         | 365–380                      |                 |                       |
| 1210.605    | 1210.593     | AIMEKLEMSK    |                              | 381–390                      |                 |                       |
| 1184.694    | 1184.691     | FQPTLLTLPR    |                              | 391–400                      |                 |                       |
| 1185.670    |              | FQPTLLTLPR    |                              |                               |                 |                       |

(Continued)
| Protein spot | Measured mass | Computed mass | Peptides identified by MALDI | Position of peptide in protein | Peptide coverage | Protein identification |
|--------------|---------------|---------------|-----------------------------|-------------------------------|-----------------|-----------------------|
| 2020–2       | 1234.494      | 1234.482      | CCHCCLLGR                   | 109–117                       | 26              | Fibulin 1, CAQ09097.1 (1–683 amino acids) |
| 1989.911     | 1989.916      | IIEVEEQEDPYLNDR | 164–179                     |                               |                 |                        |
| 1438.656     | 1438.687      | LGESCINTVGSFR | 229–241                     |                               |                 |                        |
| 815.365      | 815.370       | NVPNCGR       | 337–343                     |                               |                 |                        |
| 1174.552     | 1174.536      | GYHLINEEGTR   | 344–353                     |                               |                 |                        |
| 2152.887     | 2152.907      | CVVDVDECAPPAEPCGKGHR | 354–372                   |                               |                 |                        |
| 1022.462     | 1022.460      | CVNPSGSFR     | 373–381                     |                               |                 |                        |
| 1177.549     | 1177.540      | TGYYFDGISR    | 386–395                     |                               |                 |                        |
| 3386.602     | 3386.447      | GYQLSDVGDVTCEDIDECALPTGGHICSYR | 468–497                   |                               |                 |                        |
| 1457.600     | 1457.606      | CLAFECPENYR   | 551–561                     |                               |                 |                        |
| 1369.576     | 1369.597      | CERLPCHENR    | 568–577                     |                               |                 |                        |
| 924.423      | 924.423       | LPCHENR       | 571–581                     |                               |                 |                        |
| 2336.115     | 2336.231      | ITYHLSFEPTHIQAPAVVFR | 586–605                   |                               |                 |                        |
| 2020–3       | 1989.875      | 1989.916      | IIEVEEQEDPYLNDR | 164–179                       | 17              | Fibulin 1, CAQ09097.1 (1–683 amino acids) |
| 1438.671     | 1438.687      | LGESCINTVGSFR | 229–241                     |                               |                 |                        |
| 1174.558     | 1174.536      | GYHLINEEGTR   | 344–353                     |                               |                 |                        |
| 1022.477     | 1022.460      | CVNPSGSFR     | 373–381                     |                               |                 |                        |
| 1177.537     | 1177.540      | TGYYFDGISR    | 386–395                     |                               |                 |                        |
| 1457.696     | 1457.606      | CLAFECPENYR   | 551–561                     |                               |                 |                        |
| 1369.581     | 1369.597      | CERLPCHENR    | 568–577                     |                               |                 |                        |
| 2336.293     | 2336.231      | ITYHLSFEPTHIQAPAVVFR | 586–605                   |                               |                 |                        |
| 1997.050     | 1997.141      | KVSPHSGVVALTKPVPEPR | 634–652                   |                               |                 |                        |
| Protein 2    | 1682.83       | 1682.75       | HQDSWNGLSHEAFR | 26–39                         | 41              | Grp75, AAA67526       |
| 2092.90      | 2093.01       | GAVVGIDLGTTNNSCVAVMEGK | 53–73                     |                               |                 |                        |
| 1449.71      | 1449.71       | TTPSVVAFADGER | 86–99                       |                               |                 |                        |
| 1568.81      | 1568.83       | LYSPSIQAFVLMK | 160–173                     |                               |                 |                        |
| 1607.80      | 1607.76       | MKETAENYLHTAK | 174–187                     |                               |                 |                        |
| 1693.84      | 1693.84       | NAVITDPAYNDSQR | 188–202                     |                               |                 |                        |
| 1669.89      | 1669.91       | QATKDAQISGLNVLR | 203–218                   |                               |                 |                        |
| 1241.68      | 1241.67       | DAGQISGLNVLR | 207–218                     |                               |                 |                        |
| 1644.87      | 1644.87       | VINEPTAALAYGLDK | 219–234                   |                               |                 |                        |
| 2054.94      | 2054.95       | STNGDTFLGGEDFDQALLR | 266–284                   |                               |                 |                        |
| 1705.82      | 1705.83       | ETGVOLTKDNMALQR | 293–307                   |                               |                 |                        |
| 1360.74      | 1360.74       | AQFEGIVTDLIR | 349–360                     |                               |                 |                        |
| 1461.75      | 1461.75       | SDIGEVLVGGMTR | 378–391                     |                               |                 |                        |
| 1289.68      | 1289.67       | VQTVQVDLFGR  | 395–405                     |                               |                 |                        |
| 1807.89      | 1807.90       | SQFSTAADGQTQVEIK | 469–485                   |                               |                 |                        |
| 1591.95      | 1591.94       | LLQOFTLIGPAPR | 499–513                     |                               |                 |                        |
| 1420.69      | 1420.65       | DDIENMVNAEK  | 556–567                     |                               |                 |                        |
| 2157.02      | 2157.04       | ERVEAVNMAEGIIHDTEKT | 577–595                   |                               |                 |                        |
| 1871.89      | 1871.89       | VEAIVNMAEGIIHDTEKT | 579–595                   |                               |                 |                        |
| 2232.07      | 2232.10       | DSETGENIRQAASSLQQASLK | 626–646                   |                               |                 |                        |

(Continued)
when GST was applied to immobilized reticulocalbin. Inclusion of 20 mM EDTA in the buffer gave an interaction with a similar affinity indicating that the binding of fibulin-1C to reticulocalbin is not dependent upon the presence of Ca\(^{2+}\) (Fig 3B).

Fibulin-1C was further added to a GST-calumenin chip (Fig 3C). The dissociation constant was estimated to be around 50 nM and no interaction was seen when GST-fibulin-1C was applied to immobilized GST (Fig 3C). Thus, the interaction between fibulin-1C and reticulocalbin and calumenin was thereby verified. For reticulocalbin the binding was not dependent upon the presence of Ca\(^{2+}\).

### Surface plasmon resonance verification of C1 esterase inhibitor interaction with reticulocalbin and calumenin

C1 esterase inhibitor was applied to the reticulocalbin chip in various concentrations between 0.1 and 1 \(\mu\)M as shown in Fig 3D. The affinity was estimated to be around 1 \(\mu\)M with respect to reticulocalbin. By applying C1 esterase inhibitor to the GST-calumenin chip in various concentrations between 0.2 and 1 \(\mu\)M the affinity was estimated to be around 150 nM (Fig 3C). Thus, the interaction between fibulin-1C and reticulocalbin and calumenin was thereby verified. For reticulocalbin the binding was not dependent upon the presence of Ca\(^{2+}\).

| Protein spot | Measured mass | Computed mass | Peptides identified by MALDI | Position of peptide in protein | Peptide coverage | Protein identification |
|--------------|--------------|---------------|-------------------------------|-------------------------------|-----------------|------------------------|
| Protein 3    | 1682.82      | 1682.75       | HQDSWNGLSHEA FR              | 26–39                         | 40              | Heat shock 70 kDa protein 9 (mortalin), AAH00478 |
|              | 1156.58      | 1156.62       | AKVLENAEGAR                  | 75–85                         |                 |                        |
|              | 1708.78      | 1708.86       | IRASGDAWVEAHGK               | 144–159                       |                 |                        |
|              | 1693.83      | 1693.84       | NAVITPVAYFNDSQR              | 188–202                       |                 |                        |
|              | 1669.88      | 1669.91       | QATKDAGIQSLNVLR              | 203–218                       |                 |                        |
|              | 1241.66      | 1241.67       | DAGOISGLNVLR                 | 207–218                       |                 |                        |
|              | 1644.85      | 1644.87       | VINEPTAALAYGLDK              | 219–234                       |                 |                        |
|              | 2054.93      | 2054.95       | STNGDTFLGGEFDQALLR           | 266–284                       |                 |                        |
|              | 1705.81      | 1705.83       | ETGVDLTKDNMALQR              | 293–307                       |                 |                        |
|              | 1360.71      | 1360.74       | AQFEGIVTDLIR                 | 349–360                       |                 |                        |
|              | 2437.19      | 2437.18       | AMQDAEVSKSIDIGEVILVGMTR      | 369–391                       |                 |                        |
|              | 1461.73      | 1461.75       | SDIGEVLVGMTR                 | 378–391                       |                 |                        |
|              | 1289.65      | 1289.67       | VDOTVDLDFGRR                 | 395–405                       |                 |                        |
|              | 1807.88      | 1807.90       | SOVFSTAAADQTQOEIK            | 469–485                       |                 |                        |
|              | 1591.93      | 1591.94       | LLQFTIGIPPA PR               | 499–513                       |                 |                        |
|              | 2433.22      | 2433.21       | EQQIVIQSSGGLSIDIENMVK        | 542–563                       |                 |                        |
|              | 1420.69      | 1420.65       | DDIIENMYKNAEK                | 556–567                       |                 |                        |
|              | 1871.89      | 1871.89       | VAVNMAEIIHDTETK              | 579–595                       |                 |                        |
|              | 2232.08      | 2232.10       | DSETGENIRQASSLQASLK          | 626–646                       |                 |                        |
|              | 1044.56      | 1044.53       | LFEMAYKK                     | 647–654                       |                 |                        |

*Mass of parent ion (single charged) used for MALDI-PSD peptide sequencing.

*The band contains traces of thrombospondin-1.

doi:10.1371/journal.pone.0132283.t001

Table 1. (Continued)
Fig 2. Affinity purification of reticulocalbin binding proteins from extract of placenta. Equal volumes of homogenized placenta were applied to a column with immobilised reticulocalbin and to a column without reticulocalbin. Elution was performed similarly as described in Fig 1. Equal volumes of concentrated samples were applied to 2D gel electrophoresis with subsequent silver staining. The acidic side and the basic side of the first dimensions of the 2D gels are indicated. Several spots were eluted from the reticulocalbin column as well as the reference column. The spots marked 2018–2, 2020–2 and 2020–3 were excised from the rehydrated gels and subjected to mass spectrometry identification as given in Table 1.

doi:10.1371/journal.pone.0132283.g002
dissociation rate that approaches to an undetectable interaction at a Ca$^{2+}$ concentration around 0.1 mM. Thus, the strong interaction between C1 esterase inhibitor and calumenin is dependent upon the presence of Ca$^{2+}$ in the mM concentration range (0.5 mM to 3.5 mM) with no detectable interaction at 0.1 mM.

Immunoprecipitation with anti-calumenin and anti-reticulocalbin antiserum

In order to seek for intracellular calumenin and reticulocalbin binding proteins we used immunoprecipitation of MRC-5 V2 fibroblast proteins with polyclonal antisera against calumenin and reticulocalbin. Fig 4 shows a 2D-PAGE immunoblot of anti-calumenin antiserum using MRC-5 V2 fibroblast proteins. The antiserum is very specific with a strong reaction against calumenin (white arrow, Fig 4A and 4B). Only a slight reaction is found against two reticulocalbin spots (small black arrows, Fig 4B). Immunoprecipitation was performed using L-$^{[35}$S]-Met and L-$^{[35}$S]-Cys labelled MRC-5 V2 proteins. The immunoprecipitated and labelled
proteins were mixed with unlabeled MRC-5 V2 proteins and separated by 2D-PAGE before autoradiography. Fig 4C shows the separated proteins and Fig 4D the autoradiogram. The anti-calumenin antiserum precipitates calumenin (white arrow, Fig 4C and 4D) together with an acidic protein, No. 1 (black arrow, Fig 4C and 4D) while no proteins are precipitated without the presence of anti-calumenin antiserum (Fig 4E). The precipitated protein however did not focus very well in the acidic region of the 2D-PAGE analysis and was present in insufficient amounts for mass spectrometric determination.

A similar immunoprecipitation was performed with anti-reticulocalbin antiserum (Fig 5). Western blot analysis revealed that the antiserum reacted strongly against two reticulocalbin spots (white arrows, Fig 5A and 5B) with a cross-reaction (small black arrow, Fig 5B). Immunoprecipitation was performed using L-[35S]-Met and L-[35S]-Cys labelled MRC-5 V2 proteins. The immunoprecipitated and labelled proteins were mixed with unlabeled MRC-5 V2 proteins and separated by 2D-PAGE before autoradiography. Fig 5C shows the separated proteins and Fig 5D the corresponding autoradiogram. The anti-reticulocalbin antiserum precipitates the two reticulocalbin spots together with two spots, Nos. 2 and 3 (black arrows, Fig 5D). The anti-reticulocalbin antiserum did not precipitate the cross-reacting spot indicating that the interaction between reticulocalbin and the precipitated proteins may be real. No proteins are precipitated without the presence of anti-reticulocalbin antiserum (Fig 5E). The two spots, No. 2 and 3, were excised from the silver stained 2D-PAGE gel and subjected to in-gel digestion and mass spectrometry analysis. This revealed that spot 2 was identified as grp75 (Accession Gi:292059) and spot 3 as heat shock 70 kDa protein 9 (mortalin) (Accession GE:18645123).
Except for 3 amino acid changes of 679 amino acids the proteins are listed as identical in the SwissProt database as 75 kDa glucose regulated protein (GRP75_HUMAN).

Surface plasmon resonance verification of grp75 interaction with calumenin and reticulocalbin

We used SPR to verify the interaction of GST-grp75 with both CREC proteins immobilized to the chip as shown in Fig 6. Various concentrations of GST-grp75 were applied to the chips with immobilized calumenin and immobilized reticulocalbin. The analysis showed that GST-grp75 interacts strongly with both CREC proteins with affinities in the low nanomolar range.

Confocal microscopy

MRC-5 V2 cells do not express fibulin-1C in concentrations high enough for reliable detection of the antigen. Therefore, cells were transfected with fibulin-1C in order to reveal a putative co-localization with reticulocalbin and calumenin. As seen in Fig 7A reticulocalbin stains a perinuclear reticular network consistent with the ER localization [36] and fibulin-1C shows an overall similar localization (Fig 7B). When the pictures are merged the co-localization is apparent in the reticular network as seen by the yellow staining (Fig 7C). Thus, an interaction between fibulin-1C and reticulocalbin is possible in the ER. Similarly, calumenin being localized in the secretory pathway shows an abundant co-localization with fibulin-1C, which is apparent from the yellow staining when the pictures are merged (Fig 7F). Co-staining of MRC-
V2 fibroblasts with anti-reticulocalbin and anti-grp75 revealed partial overlap as seen by the yellow fluorescence on the merged picture indicating that interaction between grp75 and reticulocalbin is possible in the ER (Fig 7I).

Tissue localization of calumenin, reticulocalbin and fibulin

Since fibulin binds strongly to calumenin and reticulocalbin we examined the localization in arterial tissue of all three proteins by immunohistochemistry (Fig 8). Calumenin shows a strong diffuse staining (Fig 8A) in agreement with intracellular localization as well as a substantial extracellular component as it is a secreted protein [14,15]. Reticulocalbin on the other hand shows a more discrete staining mainly localized near the nuclei (Fig 8B) probably due to its...
intracellular localization. The staining of fibulin-1 (Fig 8C) has a similar pattern to the calumenin staining. The latter observation would be in line with the two proteins being secreted as a complex because of their strong interaction although further studies are needed to firmly conclude this.
Calumenin and reticulocalbin belong to the family of multiple EF-hand proteins reported to be mainly localized in various parts of the secretory pathway [1]. Although the functional properties of the CREC proteins are steadily emerging there are still several unknown aspects. The primary function of the CREC proteins seems to be interaction with and regulation of a number of proteins in the ER and SR [2]. Thus, reticulocalbin and calumenin have been reported to interact with the Sec63p protein of the protein translocase [37]. Calumenin shows a Ca\(^{2+}\)-dependent interaction with the ryanodine receptor-1 that takes part in the excitation contraction mechanism by releasing Ca\(^{2+}\) from the SR upon depolarization of the plasma membrane [26] and interacts with and inhibits the Ca\(^{2+}\)-ATPase [38]. Some of the most well described functions seem to be that calumenin interacts with and inhibits the vitamin K dependent \(\gamma\)-carboxylation system that takes care of the synthesis of a number of the coagulation factors [39].

**Discussion**

Calumenin and reticulocalbin belong to the family of multiple EF-hand proteins reported to be mainly localized in various parts of the secretory pathway [1]. Although the functional properties of the CREC proteins are steadily emerging there are still several unknown aspects. The primary function of the CREC proteins seems to be interaction with and regulation of a number of proteins in the ER and SR [2]. Thus, reticulocalbin and calumenin have been reported to interact with the Sec63p protein of the protein translocase [37]. Calumenin shows a Ca\(^{2+}\)-dependent interaction with the ryanodine receptor-1 that takes part in the excitation contraction mechanism by releasing Ca\(^{2+}\) from the SR upon depolarization of the plasma membrane [26] and interacts with and inhibits the Ca\(^{2+}\)-ATPase [38]. Some of the most well described functions seem to be that calumenin interacts with and inhibits the vitamin K dependent \(\gamma\)-carboxylation system that takes care of the synthesis of a number of the coagulation factors [39].
Recently, an extracellular function has been described that calumenin suppresses ERK1/2 signalling and cell migration by inhibiting proteolysis of fibulin-1 [32].

In order to further reveal novel functional aspects of the CREC family members one approach is to identify novel interacting proteins. We have previously identified serum amyloid P component [40] and thrombospondin-1 [33] as interacting partners with calumenin further linking this protein with the immunological defence system, haemostasis and/or thrombosis. Recently, we have shown that ERC-55 interacts with a wide variety of proteins in the secretory pathway as well as in the cytosol suggesting a broad spectrum of activities including immunity, redox homeostasis, cell cycle regulation and coagulation [5]. In the present report we have used a combination of affinity purification, immunoprecipitation and SRP analysis to identify two secretory proteins, fibulin-1C and C1 esterase inhibitor, as well as a cellular protein, grp75, that interact with both calumenin and reticulocalbin.

**Fibulin-1**

From the placenta extract we purified by 1D- and 2D-PAGE a protein using steadily increasing concentrations of NaCl from around 0.2 M up to 1 M. The protein was identified as fibulin-1. Fibulin-1 is a member of the fibulin family of proteins consisting of eight members, fibulin-1 to fibulin-8 [41,42]. Fibulin-1 has four isoforms all containing an N-terminal signal sequence, three anaphylatoxin domains nine EGF-like modules as well as a C-terminal fibulin-type module. The four variants differ in their C-terminal. Fibulin-1A consists of the sequence that is mutual for all the variants. This sequence contains 537 amino acids and a signal sequence of 29 amino acids. It is the extra varying C-terminal sequence that determine the outcome of the three others variants. These three C-terminal sequences consist of 35, 117 and 137 amino acids for the B, C, and D variants, respectively [43]. The identified fibulin-1 is the C variant. Thus, in order to verify the interaction we expressed fibulin-1C as a GST fusion protein in E. coli for surface plasmon resonance verification. This confirmed that fibulin-1C interacts with reticulocalbin as well as with calumenin with a rather high affinity. The dissociation constant was estimated to be around 50 nM. Apparently, the interaction, at least with reticulocalbin, is not dependent upon the presence of Ca²⁺. Thus even though Ca²⁺ is bound to EF-hands in the CREC proteins and to EGF motifs in fibulin, any conformational changes induced by Ca²⁺ is not important for the strength of the interaction. Reticulocalbin may interact with fibulin-1C in the ER with a chaperone function while calumenin could serve a chaperone function in the ER but also interact through the whole secretory pathway and could also interact with fibulin in the extracellular space where the Ca²⁺ concentration is high.

Fibulin-1 is a secreted Ca²⁺-binding plasma and extracellular matrix protein that is induced by estrogens in ovarian cancer cells [44]. Fibulins possess diverse roles. They interact with several protein ligands, participates in elastic fiber biology and are differentially expressed in tumors [41]. Other studies implicate fibulin-1 in hemostatic and thrombotic events. Fibulin-1 has been found to interact with the plasma protein fibrinogen and to be incorporated into fibrin clots [45]. As an extracellular matrix protein present in vessel walls, fibulin-1 may act as a mediator of platelet adhesion via a bridge of fibrinogen during vascular injury. In this way, fibulin-1 is regarded as a thrombogenic component in the earliest events of thrombus formation [46]. Calumenin has been reported to be present in thrombotic plaques [30]. Our results have revealed that calumenin and fibulin-1 strongly interacts with dissociation constant in the nanomolar range. Calumenin and fibulin-1 may thus exist in complex through the whole secretory pathway as well as being secreted as a complex although direct observations are needed to firmly conclude this. Most recently, Wang et al. also found fibulin-1D to interact with calumenin and further that calumenin protects fibulin from
degradation by matrix metalloproteinase. The result is an inhibition of cell migration through a suppression of the ERK1/2 signalling pathway [32].

**C1 esterase inhibitor**

From the 2D-PAGE analysis we identified an acidic protein eluted at 0.2 M and 0.4 M NaCl. The protein was identified as C1 esterase inhibitor. C1 esterase inhibitor consists of 478 amino acids giving an expected molecular mass of approximately 53 kDa. From the gel separation it was estimated that the protein is about 80–100 kDa in size substantially higher than the expected mass. However, the protein is highly glycosylated (49%), which may explain the about twofold higher molecular mass when compared with the expected mass [47]. C1 esterase inhibitor is a serine protease inhibitor (serpin) that influences the activation of the complement system for the prevention of bacterial infections. In addition, C1 esterase inhibitor is the primary inhibitor of factor XIIa [48]. Deficiency of C1 esterase inhibitor causes hereditary angioedema (HAE), a disease characterized by returning oedema of the face, mouth or airway [48]. In order to verify the interaction we performed surface plasmon resonance studies with C1 esterase inhibitor. Thus, it interacts with reticulocalbin with a dissociation constant around 1 μM somewhat weaker than with calumenin where the dissociation constant is estimated to about 150 nM. The interaction, at least with calumenin is dependent upon Ca^{2+} in the mM range. With the concentrations of Ca^{2+} in the secretory pathway it seems possible that C1 esterase inhibitor may interact with reticulocalbin and calumenin mainly in the ER and with calumenin in the whole secretory pathway as well as extracellularly. C1 esterase inhibitor does not contain obvious Ca^{2+} binding domains, neither EF-hands nor EGF motifs, so it is likely that Ca^{2+}-induced conformational changes in the CREC protein is responsible for the changes in the binding strength observed.

**Grp75**

By immunoprecipitation we detected grp75 (or mortalin) as a putative interacting partner with reticulocalbin. Subsequent SRP analysis showed that grp75 interacted with calumenin as well as with reticulocalbin at rather high affinities with dissociation constants at the low nanomolar level.

Grp75 belongs to the chaperone heat shock protein (hsp70) family of proteins and in different studies it has been localized in the mitochondria, ER, plasma membrane, cytoplasmic vesicles and the cytosol [49]. Thus, with calumenin and reticulocalbin localized in the ER there seems to be a possibility for interactions here. Grp75 is differentially distributed in normal and transformed cells [50] and it has in several cases been observed in association with malignant transformation of cells.

**Conclusion**

By a combination of affinity purification, immunoprecipitation and SRP analysis we identified three proteins, fibulin-1C, C1 esterase inhibitor and grp75 capable of interacting with two CREC proteins, calumenin and reticulocalbin. Fibulin-1C showed a strong reaction with both proteins with a $K_D$ around 50 nM, and the binding was not particularly dependent upon the presence of Ca^{2+} at least in case of reticulocalbin. C1 esterase inhibitor interacts with reticulocalbin with an affinity around 1 μM and somewhat stronger with calumenin with an affinity at 150 nM. At least for calumenin, the binding was strongly dependent upon the presence of Ca^{2+} in the mM range. Grp75 was found to interact with the two CREC proteins with an affinity in the low nanomolar range.
These identified interactions largely confirm a number of previous discovered functions such as participation in chaperone activity, control of cell proliferation and cellular aging (grp75), modulation of cellular transformation and participation in haemostasis and thrombosis (fibulin-1), as well as modulation of the complement system in fighting bacterial infection (C1 esterase inhibitor).

Acknowledgments
We thank Dr. Ozawa for the kind gift of the pGEX vector containing reticulocalbin. The antibody against fibulin-1 was obtained as a kind gift from Dr. Argrawes. Inge Kjærgaard, Kirsten Peterslund and Anne Marie Bundsgaard are thanked for expert technical assistance.

Author Contributions
Conceived and designed the experiments: GAWH CJ LMR HV BH. Performed the experiments: GAWH ML CJ CC HV BH. Analyzed the data: GAWH ML CJ CC LMR HV BH. Contributed reagents/materials/analysis tools: GAWH CJ LMR BH. Wrote the paper: GAWH ML CJ CC LMR HV BH.

References
1. Honoré B, Vorum H. The CREC family, a novel family of multiple EF-hand, low-affinity Ca2+-binding proteins localised to the secretory pathway of mammalian cells. FEBS Lett. 2000; 466: 11–18. PMID: 10648803
2. Honoré B. The rapidly expanding CREC protein family: members, localization, function, and role in disease. Bioessays. 2009; 31: 262–277. doi:10.1002/bies.200806186 PMID: 19260022
3. Ozawa M. Cloning of a human homologue of mouse reticulocalbin reveals conservation of structural domains in the novel endoplasmic reticulum resident Ca2+-binding protein with multiple EF-hand motifs. J Biochem. 1995; 117: 1113–1119. PMID: 8586628
4. Weis K, Griffiths G, Lamond AI. The endoplasmic reticulum calcium-binding protein of 55 kDa is a novel EF-hand protein retained in the endoplasmic reticulum by a carboxyl-terminal His-Asp-Glu-Leu motif. J Biol Chem. 1994; 269: 19142–19150. PMID: 8034671
5. Ludvigsen M, Jacobsen C, Maunsbach AB, Honoré B. Identification and characterization of novel ERC-55 interacting proteins: Evidence for the existence of several ERC-55 splicing variants; including the cytosolic ERC-55-C. Proteomics. 2009; 9: 5267–5287. doi: 10.1002/pmc.200900321 PMID: 19927312
6. Tsuji A, Kikuchi Y, Sato Y, Koide S, Yuasa K, Nagahama M, et al. A proteomic approach reveals transient association of reticulocalbin-3, a novel member of the CREC family, with the precursor of subtilisin-like proprotein convertase, PACE4. Biochem J. 2006; 396: 51–59. PMID: 16433634
7. Scherer PE, Ledekrømer GZ, Williams S, Fogliano M, Baldini G, Lodish HF. Cab45, a novel Ca2+-binding protein localized to the Golgi lumen. J Cell Biol. 1996; 133: 257–268. PMID: 8609160
8. Lam PP, Hyvarinen K, Kauppi M, Cosen-Binker L, Laitinen S, Keranen S, et al. A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on amylase secretion by pancreatic acini. Mol Biol Cell. 2007; 18: 2473–2480. PMID: 17442889
9. Yabe D, Nakamura T, Kanazawa N, Tashiro K, Honjo T. Calumenin, a Ca2+-binding protein retained in the endoplasmic reticulum with a novel carboxyl-terminal sequence, HDEF. J Biol Chem. 1997; 272: 18232–18239. PMID: 9218460
10. Vorum H, Liu X, Madsen P, Rasmussen HH, Honoré B. Molecular cloning of a cDNA encoding human calumenin, expression in Escherichia coli and analysis of its Ca2+-binding activity. Biochim Biophys Acta. 1998; 1386: 121–131. PMID: 9675259
11. Hseu MJ, Yen CH, Tzeng MC. Crocalbin: a new calcium-binding protein that is also a binding protein for crototoxin, a neurotoxic phospholipase A2. FEBS Lett. 1999; 445: 440–444. PMID: 10094905
12. Jung DH, Kim DH. Characterization of isoforms and genomic organization of mouse calumenin. Gene. 2004; 327: 185–194. PMID: 14983715
13. Feng H, Chen L, Wang Q, Shen B, Liu L, Zheng P, et al. Calumenin-15 facilitates filopodia formation by promoting TGF-beta superfamily cytokine GDF-15 transcription. Cell Death Dis. 2013; 4: e870. doi: 10.1038/cddis.2013.403 PMID: 24136234
14. Vorum H, Hager H, Christensen BM, Nielsen S, Honoré B. Human calumenin localizes to the secretory pathway and is secreted to the medium. Exp Cell Res. 1999; 248: 473–481. PMID: 1022138

15. Wang Q, Feng H, Zheng P, Shen B, Chen L, Liu L, et al. The intracellular transport and secretion of calumenin-1/2 in living cells. PLoS One. 2012; 7: e35344. doi: 10.1371/journal.pone.0035344 PMID: 22514732

16. Grønborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006; 5: 157–171. PMID: 16215274

17. Chen L, Xu S, Liu L, Wen X, Xu Y, Chen J, et al. Cab4SS inhibits the ER stress-induced IRE1-JNK pathway and apoptosis via GRP78/Bip. Cell Death Dis. 2014; 5: e1219. doi: 10.1038/cddis.2014.193 PMID: 24810055

18. Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, et al. Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem. 2008; 104: 2298–2309. doi: 10.1002/jcb.21785 PMID: 18561328

19. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science. 1995; 269: 529–531. PMID: 7624774

20. Liu Z, Brattain MG, Appert H. Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. Biochem Biophys Res Commun. 1997; 231: 283–289. PMID: 9070264

21. Nimmrich I, Erdmann S, Melchers U, Finke U, Hentsch S, Moyer MP, et al. Seven genes that are differentially transcribed in colorectal tumor cell lines. Cancer Lett. 2000; 160: 37–43. PMID: 11098082

22. Yu LR, Zeng R, Shao XX, Wang N, Xu YH, Xia QC. Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis. 2000; 21: 3058–3068. PMID: 11001323

23. Carper D, John M, Chen Z, Subramanian S, Wang R, Ma W, et al. Gene expression analysis of an H_2O_2-resistant lens epithelial cell line. Free Radic Biol Med. 2001; 31: 90–97. PMID: 11425494

24. Huang YH, Chang AY, Huang CM, Huang SW, Chan SH. Proteomic analysis of lipopolysaccharide-induced apoptosis in PC12 cells. Proteomics. 2002; 2: 1220–1228. PMID: 12362339

25. Sahoo SK, Kim do H. Characterization of calumenin in mouse heart. BMB Rep. 2010; 43: 158–163. PMID: 20356454

26. Jung DH, Mo SH, Kim DH. Calumenin, a multiple EF-hands Ca^{2+}-binding protein, interacts with ryanodine receptor-1 in rabbit skeletal sarcoplasmic reticulum. Biochem Biophys Res Commun. 2006; 343: 34–42. PMID: 16527250

27. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J. 2001; 15: 2542–2544. PMID: 11641264

28. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2009; 87: 445–451. doi: 10.1038/cpt.2009.291 PMID: 20200517

29. Teng L, Kerbiriou M, Taiya M, Le Hir S, Mignen O, Benz N, et al. Proteomic identification of calumenin as a G551D-CFTR associated protein. PLoS One. 2012; 7: e40173. doi: 10.1371/journal.pone.0040173 PMID: 22788251

30. Coppingier JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004; 103: 2096–2104. PMID: 14630798

31. Østergaard M, Hansen GAW, Vorum H, Honoré B. Proteomic profiling of fibroblasts reveals a modulating effect of extracellular calumenin on the organization of the actin cytoskeleton. Proteomics. 2006; 6: 3509–3519. PMID: 16691550

32. Wang Q, Shen B, Chen L, Zheng P, Feng H, Hao Q, et al. Extracellular calumenin suppresses ERK1/2 signaling and cell migration by protecting fibulin-1 from MMP-13-mediated proteolysis. Oncogene. 2015; 34: 1006–1018. doi: 10.1038/onc.2014.52 PMID: 24832695

33. Hansen GAW, Vorum H, Jacobsen C, Honoré B. Calumenin but not reticulocalbin forms a Ca^{2+}-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis. Mol Cell Biochem. 2009; 320: 25–33. doi: 10.1007/s11010-008-9895-1 PMID: 18688996

34. Honoré B, Vorum H, Pedersen AE, Buus S, Claësson MH. Changes in protein expression in p53 deleted spontaneous thymic lymphomas. Exp Cell Res. 2004; 295: 91–101. PMID: 15051493

35. Cangemi C, Skov V, Poulsen MK, Funder J, Twal WO, Gall MA, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem. 2011; 57: 1556–1565. doi: 10.1373/clinchem.2011.162966 PMID: 21926180
36. Ozawa M, Muramatsu T. Reticulocalbin, a novel endoplasmic reticulum resident Ca\textsuperscript{2+}-binding protein with multiple EF-hand motifs and a carboxyl-terminal HDEL sequence. J Biol Chem. 1993; 268: 699–705. PMID: 8416973

37. Tyedmers J, Lerner M, Nastainczyk W, Zimmermann R. Calumenin and reticulocalbin are associated with the protein translocase of the mammalian endoplasmic reticulum. J Biol Sci. 2005; 5: 70–75.

38. Sahoo SK, Kim T, Kang GB, Lee JG, Eom SH, Kim DH. Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum. J Biol Chem. 2009; 284: 31109–31121. doi: 10.1074/jbc.M109.031989 PMID: 19740751

39. Wajih N, Sane DC, Hutson SM, Wallin R. The Inhibitory Effect of Calumenin on the Vitamin K-dependent gamma-Carboxylation System: characterization of the system in normal and warfarin-resistant rats. J Biol Chem. 2004; 279: 25276–25283. PMID: 15075329

40. Vorum H, Jacobsen C, Honoré B. Calumenin interacts with serum amyloid P component. FEBS Lett. 2000; 465: 129–134. PMID: 10631319

41. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep. 2003; 4: 1127–1131. PMID: 14647206

42. Cangemi C, Hansen ML, Argraves WS, Rasmussen LM. Fibulins and their role in cardiovascular biology and disease. In: Gregory SM, editor. Advances in Clinical Chemistry: Elsevier; 2014. pp. 245–265. doi: 10.1016/bs.acc.2014.09.008 PMID: 25735864

43. Pan TC, Kostka G, Zhang RZ, Timpl R, Chu ML. Complete exon-intron organization of the mouse fibulin-1 gene and its comparison with the human fibulin-1 gene. FEBS Lett. 1999; 444: 38–42. PMID: 10037144

44. Clinton GM, Rougeot C, Derancourt J, Roger P, Defrenne A, Godyna S, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A. 1996; 93: 316–320. PMID: 8552629

45. Tran H, Tanaka A, Litvinovich SV, Medved LV, Haudenschild CC, Argraves WS. The interaction of fibulin-1 with fibrinogen. A potential role in hemostasis and thrombosis. J Biol Chem. 1995; 270: 19458–19464. PMID: 7642629

46. Godyna S, Diaz-Ricart M, Argraves WS. Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood. 1996; 88: 2569–2577. PMID: 8839849

47. Davis AE 3rd. Hereditary and acquired deficiencies of C1 inhibitor. Immunodef Rev. 1989; 1: 207–226. PMID: 2698641

48. Davis AE 3rd, Cai S, Liu D. The biological role of the C1 inhibitor in regulation of vascular permeability and modulation of inflammation. Adv Immunol. 2004; 82: 331–363. PMID: 14975261

49. Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers RN, Bick RJ, et al. Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res Commun. 2000; 275: 174–179. PMID: 10944461

50. Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y. Identification of a novel member of mouse hap70 family. Its association with cellular mortal phenotype. J Biol Chem. 1993; 268: 6615–6621. PMID: 8454632